Royalty Adjustments Clause Samples
POPULAR SAMPLE Copied 1 times
Royalty Adjustments. (i) During any part of the Royalty Term for a Licensed Product in a country in which there is no Valid Claim of the vTv Patents Covering such Licensed Product or the Compound contained therein, or the manufacture or use of such Licensed Product or Compound contained therein, in such country, but there is Regulatory Exclusivity for such Licensed Product in such country, the royalty payable with respect to Net Sales of such Licensed Product in such country shall be reduced by [***]. During any part of the Royalty Term for a Licensed Product in a country in which (A) there is no Valid Claim of the vTv Patents Covering such Licensed Product or the Compound contained therein, or the manufacture or use of such Licensed Product or Compound contained therein, in such country, and (B) there is no Regulatory Exclusivity for such Licensed Product in such country, the royalty payable with respect to Net Sales of such Licensed Product in such country shall be reduced by [***]. The foregoing reductions will be calculated by determining the portion of total Net Sales of the relevant Licensed Product in a calendar quarter that is attributable to the country in which such reduction applies, and determining the total royalties for such Licensed Product without reduction, and then reducing by [***] or [***], as applicable, the applicable portion (based on Net Sales of such Licensed Product in such country as a percentage of total Net Sales of such Licensed Product) of total royalties attributable to such Licensed Product in such country.
(ii) If Reneo or any of its Affiliates or Sublicensees, as applicable, determines, in its reasonable judgment, that it is necessary to obtain a license from any Third Party (each a “Third Party License”) under any Patents in order to manufacture, use, sell, offer for sale or import a Licensed Product in a country, then Reneo may deduct [***] of any royalty amount (or comparable payment based on sales of Licensed Product) paid by Reneo or its Affiliate or Sublicensee in any calendar quarter to such Third Party with respect to sales of such Licensed Product in such country under such Third Party License from the royalty payment that would otherwise be due with respect to Net Sales of such Licensed Product in such country in such calendar quarter pursuant to Section 3.5(a); provided, however, that in no event shall any royalty payment to vTv on Net Sales of any Licensed Product in any country in any calendar quarter be reduced to less than [***...
Royalty Adjustments. Product Royalties shall be subject to adjustment as a result of the events set forth below.
Royalty Adjustments. Core IP Royalties shall be subject to adjustment as a result of the events set forth below.
Royalty Adjustments. The following adjustments shall be made, on a Licensed Product-by-Licensed Product and country-by-country basis, to the royalties payable pursuant to this Section 5.5:
Royalty Adjustments. Except as otherwise set forth in this Agreement, royalties due hereunder are subject to adjustment as set forth below (such adjustments to be prorated for the Calendar Quarter in which the adjustment becomes applicable):
Royalty Adjustments. The following adjustments shall be made, on a Product-by-Product and country-by-country basis, to the royalties payable pursuant to Section 3.5.1, in each case, subject to the limitations set forth in Section 3.5.4:
Royalty Adjustments. (a) Subject to Section 7.5(e), BMS may deduct from the royalties it would otherwise owe pursuant to Section 7.4 for a particular BMS Product, [ * ]. BMS shall limit its deductions of Third Party royalty payments with respect to Patents that claim the use of a BMS Selected Target in oncology [ * ], to payments made on account of sales reasonably attributable to use in such fields.
(b) Subject to Section 7.5(e), BMS may deduct, from the royalties it would otherwise owe pursuant to Section 7.4(b)(ii) for a particular BMS Collaboration Product containing a Lead Compound or Back-up Compound provided by Exelixis pursuant to Section 3.5(b), [ * ]. BMS shall limit its deductions of Third Party royalty payments with respect to Patents that claim the use of a Lead Compound or Back-up Compound in oncology [ * ], to payments made on account of sales reasonably attributable to use in such fields.
(c) Subject to Section 7.5(e), BMS may reduce the applicable royalty rate set forth in Section 7.4 by [ * ].
(d) Subject to Section 7.5(e), BMS may reduce the applicable royalty rate set forth in Section 7.4 by [ * ].
(e) Regardless of the number of royalty deductions or royalty rate reductions set forth in this Section 7.5 that may apply to a particular BMS Product, the minimum royalty rate paid by BMS pursuant to this Amended and Restated Agreement shall be [ * ].
(f) For each BMS Product with activity against a Hybrid BMS Selected Target, the royalty payments under Section 7.4 (and any deductions or adjustments thereto permitted under this Section 7.5) shall be based solely on Net Sales of such product in oncology [ * ]. Prior to the first commercial sale of a particular BMS Product with activity against a Hybrid BMS Selected Target, the Parties shall agree in writing upon the methodology to be used to allocate the Net Sales of such product between (i) the Net Sales attributable to use in oncology and all defined fields for which BMS took a license from Exelixis pursuant to Section 5.2(b) and (ii) the Net Sales attributable to use in the principle indication(s) specified in the DP1 Approval for such Hybrid BMS Selected Target.
Royalty Adjustments. The receipt or acceptance by VDI and Agent/SPI of any royalty statements furnished pursuant to this Agreement, or the receipt or acceptance of any royalty payments made, shall not preclude VDI and Agent/SPI from questioning their accuracy at any time. If any inconsistencies or mistakes are discovered in such statements or payments, appropriate adjustments shall be made immediately by the parties. The Licensee shall pay VDI interest on a late royalty payment at an annual rate of ****% over the prevailing prime interest rate in effect at Orlando, Florida, on the date on which such late royalty payment should have been received by VDI.
Royalty Adjustments. In making the royalty payments due Tessera, Licensee may subtract from such royalty payments any preceding royalty payments for royalty bearing Licensed Products that are returned to Licensee from Licensee’s customers (“Royalty Adjustment”). However, if at any time such returned Licensed Products are resold by Licensee, Licensee shall pay a royalty to Tessera for such resold Licensed Products, as set forth in the Agreement. Before a Royalty Adjustment can be so subtracted, Licensee must have originally paid a royalty on the particular returned Licensed Product. All Royalty Adjustments must be specified with the information set forth in Attachment C.
Royalty Adjustments. In making the royalty payments due Tessera, Licensee may subtract from such royalty payments any preceding royalty payments for defective royalty bearing TCC packages that are returned to Licensee from Licensee’s customers (“Royalty Adjustment”). However, if at any time such defective TCC packages are resold by Licensee, Licensee shall pay a royalty to Tessera for such resold TCC packages, as set forth in the Agreement and this First Addendum. Before a Royalty Adjustment can be so subtracted, Licensee must have originally paid a royalty on the particular returned TCC package. All Royalty Adjustments must be specified with the information set forth in Addendum Attachment A.